Evidence map›Paper›PMID 12695431›Full record

ReviewHeart (British Cardiac Society)2003

The obesity epidemic: can we turn the tide?

I Campbell

Registry-linked trialAbstract readReview
In one paragraph

Review in Heart (British Cardiac Society), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00941382 (Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00941382 phase3unknown statusstarted 2008, after this paper: background citation

Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients

Ran2008Enrolled60Registered outcomes3Posted comparisons0ConditionsObesityArmsMetformin, Sibutramine, Sibutramine-Metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

I CampbellNational Obesity Forum, PO Box 6625, Nottingham NG2 5PA, UK. icampbell@nationalobesityforum.org.uk

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity has reached epidemic proportions in the UK. It is important because of the associated co-morbidities, which include cardiovascular disease, type 2 diabetes, and osteoarthritis. The prevalence of obesity has increased because of a combination of excessive calorific intake (for example, from increased intake of energy dense foods) and insufficient energy expenditure (associated with a sedentary lifestyle). Weight loss of 5-10%, which can be achieved in primary care, is associated with significant health benefits. Obesity treatment in primary care includes lifestyle modification and drug treatment. The prevention and treatment of obesity cannot, however, be left solely to health professionals. Action is needed by government, the food industry, and society as a whole.

Indexed as

ObesityBody Mass IndexCoronary DiseaseDiabetes Mellitus, Type 2Disease OutbreaksFemaleHumansMaleMyocardial InfarctionPrevalenceRisk FactorsUnited KingdomUnited States

Identifiers

PMID12695431
PMCPMC1876296

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.